555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States

BACKGROUND: Raltegravir (RAL) 400 mg twice-daily (RAL BID) has been an integral part of antiretroviral therapy (ART) in both ART naïve and experienced HIV-1 infected patients for the last decade. In 2017, RAL 1,200 mg (2 × 600 mg), a once-daily formulation (RAL QD) was approved. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lackey, Philip, Schulman, Kathy, Fusco, Jennifer, Arduino, Jean Marie, Prajapati, Girish, Fusco, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255467/
http://dx.doi.org/10.1093/ofid/ofy210.563

Ejemplares similares

Ejemplares similares